Bruce Cozadd: Rob?
Rob Iannone: Yes, thank you for the question. So, the liver toxicity associated with 994 was known at the time that we entered into the partnership with Sumitomo, and we focused on chemical series that we thought were distinct enough such that that wouldn’t — at risk of liver toxicity wouldn’t be carried over. And so, we do think that our molecule is substantially differentiated from the chemical series that you referred to.
Operator: Thank you. The next question comes from the line of Mohit Bansal with Wells Fargo. Your line is now open.
Mohit Bansal: Great. And congrats on all the progress. So maybe like one question regarding the authorized generics for Xyrem, do you think they will have any impact on IH market as such because in our talk to doctors, they think that they can prescribe it as long as we cover payers would probably cover it. So do you see this as a threat because doctors could use it off-label?
Bruce Cozadd: Yes. Well, I’ll remind you that Xyrem did not do a comprehensive clinical program in the way that Xywav has in IH. There’s slightly different dosing information in the label. And while you’re right that physicians can prescribe the product that does not always mean that, that product will be successfully reimbursed. Kim, any comments you want to make on the marketplace?
Kim Sablich: Yes, sure. So yes, we’ve seen traditionally the payer — that HCPs have had trouble getting coverage for oxybate for idiopathic hypersomnia because payers restricted it with the introduction of byway for idiopathic hypersomnia we have achieved nice coverage as we do with narcolepsy of 90% of commercial lives having coverage. There is utilization management criteria in place there and certainly heavier utilization management criteria around non indicated products. So we feel confident that while it’s a small portion of health care plans may cover high sodium oxybate in particular, the AG for idiopathic hypersomnia. Most of them are following the FDA-approved label and Xywav is the only FDA-approved treatment for idiopathic hypersomnia.
Bruce Cozadd: And Rob, maybe you could just expand a little bit on that slightly different dosing information?
Rob Iannone: Yes, Bruce, specifically with regard to narcolepsy or IH or?
Bruce Cozadd: I meant IH, but you can talk about dosing flexibility generally.
Rob Iannone: Sure. So starting with IH then, the clinical trial allowed for an initial dose of up to 6 grams. And at the time, it was designed that way because there was some uncertainty around whether IH patients would make up to take that second dose. What we found in the clinical trials that with initiation of Xywav, patients with IH improved substantially. And in fact, we’re able to go ahead and take the second dose. And overall, that was the more common dosing regimen, even though in the trial, and we find that to be the case in clinical practice as well along those lines for narcolepsy. As you know, Xywav also has dosing flexibility to allow for uneven doses. And we find that patients really do prefer this Oftentimes, schedules are different from one patient to another. But even within a patient, schedules made different day to day, week days, weekends depending on family obligations, and they like the flexibility of uneven doses potentially.
Operator: Thank you. The next question comes from the line of Joon Lee with Truist Securities. Your line now is open.
Joon Lee: Congrats on the quarter. How do you quantify the trade-off between having a once a night drug with high sodium versus twice a night drug with no sodium? Isn’t having to wake up in the middle of also unhealthy? And as a quick follow-up, do you have any views on reboxetine currently in Phase III/IV for narcolepsy with data expected in the fourth quarter?
Bruce Cozadd: Yes. Rob, maybe I could have you jump in a little bit on the nighttime impact of oxybate therapy?
